Chairman
Dr Tony BaxterTony is CEO of Cyprotex PLC which has recently exceeded City expectations on profits.Cyprotex is a provider of services to the Pharmaceutical industry. Dr Baxter was formerly the founding CEO of Argenta Discovery Limited, a leading drug discovery services and proprietary therapeutics company backed by substantial venture capital investment. In less than four years from the company's start-up in 1999, he grew services revenue to over £9 million which included building a pipeline of novel therapeutic programmes. He then led the successful merger of the business with biotech company, Etiologics Limited. Prior to this, Dr Baxter was Chief Scientific Officer of Oxford Asymmetry International plc and helped build the business from an early stage company to its flotation on the LSE and then to its eventual merger with Evotec in 2000 at a valuation of £316 million. Most recently, Dr Baxter lead the turnaround of deltaDOT Limited, a proteomics / genomics platform technology company, which involved fundraising of £8.3 million. He is currently Non-Executive Chairman of Equinox Pharma Ltd., an Imperial College spin out company focussing on development of 'machine learning' for iterative and multi-parametric drug discovery projects.
Executive Directors
Dr Andrew WattsAndrew is currently a Lecturer in Medicinal Chemistry University of Bath with over 10 years experience in carbohydrate research, including synthesis, inhibitor design, mechanistic enzymology and development of novel technologies. He has authored several high impact research papers in the field including the determination of a novel catalytic mechanism for neuraminidases, and was part of the team that published the first X-ray structure of a sialyl transferase.
Dr Amanda MacKenzieAmanda MacKenzie is a Lecturer in Pharmacology with over 10 years research experience in field of ion channels, immunology and haematology. Her experience includes a postdoctoral fellowship position in Glaxo Wellcome and a senior fellowship funded by AstraZeneca mentored by Prof. Alan North. She has authored several high impact research papers and reviews in the field of membrane ion channel signalling and small protein cytokine signalling.
Non-Executive Director
Prof. William BainsWilliam is a scientist and entrepreneur. He has 15 years' experience in creating, valuing and implementing new technology in start-up companies, including Ark Therapeutics and Vectura, and has started 4 companies including Amedis Pharmaceuticals Ltd.. He is author of over 100 articles and 3 books, teaches entrepreneurship and company financing at Cambridge University.
Mark WarneMark has worked for IP Group plc since 2008, identifying and commercialising intellectual property in the life science arena from UK universities. He also manages IP Group’s partnerships with the Universities of Bristol and Bath. Mark joined IP Group from pre-clinical drug discovery CRO, Exelgen, where he was managing director. Mark spent eight years at Exelgen (formerly Tripos Discovery Research) where he also held positions in Licensing and Strategic Affairs, Project Management and Research. He has a PhD in computational chemistry, an MSc in colloid science and BSc in chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry.